Revance Therapeutics, Inc.

Welcome to the Retham's Therapeutics quarter and full year 2020 financial results and corporate update conference call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star followed by one on your touchtone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this call is being recorded today, February 22, 2021. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revenants. Please go ahead.

Thank you, Faith. Joining us on the call today from Revenants is President and Chief Executive Officer Mark Foley, Chief Financial Officer Toby Schilke, Chief Operating Officer and President of R&D and Product Operations, Dr. Abhay Joshi, Chief Commercial Officer, Aesthetics and Therapeutics, Dustin Suits, President of Innovation and Technology, Aubrey Rankin, and Senior Vice President, Clinical Development, Dr. Roman Rubio. During this call, management will make forward-looking statements, including statements related to Revance's 2021 guidance, the clinical development of our product candidates, business strategy and planned operations, commercial launch of the RHA collection of dermal fillers and Henton D. Fintech platform, the timing of any potential approval of Daxibotulatum Toxin A for injection by the FDA, the market opportunity of our aesthetics and therapeutics franchises, milestone expectations and expected cash runway and financial performance. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the company describes in the section titled Risk Factors in our quarterly report on Form 10Q as filed with the SEC on November 7, 2020. ReVance undertakes no obligation or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. Also on today's call, we will present both GAAP and non-GAAP financial measures. A reconciliation of non-GAAP to GAAP measures is included in our earnings release. With that, I will turn the call over to Mark Foley. Mark?

Thank you, Jessica. Good afternoon, everyone, and thank you for joining our fourth quarter and full year 2020 earnings conference call. 2020 was truly a transformational year for Revance. Our team more than doubled in size. We advanced both of our aesthetics and therapeutics pipelines and strengthened our balance sheet, extending our cash runway into 2024. We also integrated HintMD, a next-generation point-of-sale payment and consumer loyalty platform for for aesthetic practices that provides us with a diversified revenue stream. This year culminated with our successful transition into a commercial entity as we launched the RHA collection of dermal fillers and the HIN-MD FinTech platform. These would all be significant accomplishments in a normal year, but even more noteworthy against the backdrop of the global COVID-19 pandemic. I'm incredibly proud of our team for coming together during these challenging times and delivering on our key objectives for the year. Before I cover our fourth quarter highlights and milestones for this year, I'd like to review the results from our Juniper Phase II trial, Daxibotulinum Toxin A for injection for adult upper limb spasticity, which we will refer to as adult ULS on this call. This is our second muscle movement disorder clinical program for Daxibotulinum Toxin A for injection, and we are very pleased with the data from the Phase II study. Before I pass the call over to Roman to review the study, Let me talk a little bit more about upper limb spasticity. Adult ULS is a condition that affects movement in the arms and hands, making muscles stiff, flexed, and sometimes spasm. It is most often caused by stroke, disease, or traumatic brain injury. Although not life-threatening, it can be painful and debilitating, impacting a patient's ability to perform daily tasks. Botulinum toxin injections have shown to be effective in relieving many symptoms of spasticity particularly when combined with physical therapy. Injections are typically administered by physiatrists and neurologists who treat problems with the brain and nervous system. Total spasticity, which includes upper and lower limb spasticity, is one of the largest of the muscle movement disorders, representing a $620 million global opportunity in 2020 and expected to grow to over $1 billion by 2025. The prevalence of spasticity is estimated to be 12 million people worldwide. However, less than 20% of patients receive treatment. As with cervical dystonia, there are challenges with the currently approved botulinum toxins in the treatment of adult ULS. In present-day practice, patients are typically injected every 12 weeks. However, patients often experience a return of symptoms prior to the approved treatment interval by payers. For these reasons, there is a significant unmet need in this patient population, similar to what is seen in cervical dystonia patients, for a long-lasting and more cost-effective therapy. We hope that daxibotulinum toxin A for injection, once approved, would encourage a greater population of patients with this condition to seek treatment. Now, I'll pass the call to Roman to review the trial design and results. Roman?